The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Newly Diagnosed Acute Myeloid Leukaemia Patients

References

• Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M; Swedish Acute Leukemia Registry G. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890–3899.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606. doi:10.1016/S0140-6736(18)31041-9
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–2086. doi:10.1038/leu.2013.207
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Polliack A, Shenhar-Tsarfaty S, et al. Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia. Ann Med. 2017;49:75–82. doi:10.1080/07853890.2016.1232860
   PubMed Web of Science ®Google Scholar
• Qin W, Yuan Q, Wu J, Yu H, Wang Y, Chen Q. Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma. 2019;60:358–366. doi:10.1080/10428194.2018.1482540
   PubMed Web of Science ®Google Scholar
• Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. J Parenter Enteral Nutr. 2019;43:181–193. doi:10.1002/jpen.1451
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309–324. doi:10.1038/nri.2017.142
   PubMed Web of Science ®Google Scholar
• Wang N, Desai A, Ge B, et al. Prognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2020;61:641–649. doi:10.1080/10428194.2019.1686499
   PubMed Web of Science ®Google Scholar
• Lauriane FC, Julien B, Marc M, et al. Serum albumin or body mass index: which prognostic factor for survival in patients with acute myeloblastic leukaemia? Hematol Oncol. 2018;37:80–84
   PubMed Web of Science ®Google Scholar
• Doucette K, Percival ME, Williams L, et al. Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia. Hematol Oncol. 2021;39(5):697–706.doi:10.1002/hon.2925
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016;23:900–907. doi:10.1245/s10434-015-4948-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu K, Ye B, Liang W, Ren Y. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer. Cancer Med. 2018;7:105–113. doi:10.1002/cam4.1270
   PubMed Web of Science ®Google Scholar
• Otowa Y, Nakamura T, Yamamoto M, et al. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus. 2017;30:1–5. doi:10.1093/dote/dox107
   PubMed Web of Science ®Google Scholar
• Tang HN, Pan BH, Wang L, Zhu HY, Li JY. C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: a clinical analysis of 322 cases. Transl Oncol. 2021;14:101035. doi:10.1016/j.tranon.2021.101035
   PubMed Web of Science ®Google Scholar
• Heini AD, Hugo R, Berger MD, Novak U, Bacher U, Pabst T. Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. Hematol Oncol. 2020;38:74–81. doi:10.1002/hon.2696
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Loh KP, Tooze JA, Nicklas BJ, et al. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020;11:410–416. doi:10.1016/j.jgo.2019.03.014
   PubMed Web of Science ®Google Scholar
• Manerba M, Di Ianni L, Govoni M, Roberti M, Recanatini M, Di Stefano G. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells. Eur J Pharm Sci. 2017;96:37–44. doi:10.1016/j.ejps.2016.09.014
   PubMed Web of Science ®Google Scholar
• Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6:748–773. doi:10.1039/c3mt00347g
   PubMed Web of Science ®Google Scholar
• Lebon D, Vergez F, Bertoli S, et al. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leuk Res. 2015;39:818–821. doi:10.1016/j.leukres.2015.05.001
   PubMed Web of Science ®Google Scholar
• Tachibana T, Andou T, Tanaka M, et al. Clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia: a YACHT multicenter retrospective study. Clin Lymphoma Myeloma Leuk. 2018;18:415–421. doi:10.1016/j.clml.2018.03.009
   PubMed Web of Science ®Google Scholar
• Ihlow J, Gross S, Sick A, et al. AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival. Leuk Lymphoma. 2019;60:69–77. doi:10.1080/10428194.2018.1461860
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–810. doi:10.1245/s10434-014-4048-0
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Snook RW 2nd. Monoclonal antibodies that recognize lacto-N-fucopentaose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/HMac-1/gp 150,95) and CR1 on human neutrophils. J Immunol. 1987;139:1631–1639.
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol. 1989;72:161–166. doi:10.1111/j.1365-2141.1989.tb07677.x
   PubMed Web of Science ®Google Scholar
• Tien HF, Wang CH, Lin MT, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet. 1995;84:60–68. doi:10.1016/0165-4608(95)00084-4
   PubMed Web of Science ®Google Scholar
• Chisini M, Stefanizzi C, Ceglie T, et al. Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. Hematol Oncol. 2017;35:804–809. doi:10.1002/hon.2331
   PubMed Web of Science ®Google Scholar
• Derolf AR, Bjorklund E, Mazur J, Bjorkholm M, Porwit A. Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia. Leuk Lymphoma. 2008;49:1279–1291. doi:10.1080/10428190802123994
   PubMed Web of Science ®Google Scholar
• Repp R, Schaekel U, Helm G, et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom. 2003;53:11–19. doi:10.1002/cyto.b.10030
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61:885–891. doi:10.1016/j.cyto.2012.12.023
   PubMed Web of Science ®Google Scholar
• Stevens AM, Miller JM, Munoz JO, Gaikwad AS, Redell MS. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv. 2017;1:1387–1397. doi:10.1182/bloodadvances.2017007856
   PubMed Web of Science ®Google Scholar
• Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765–3770. doi:10.1182/blood.V95.12.3765
   PubMed Web of Science ®Google Scholar
• Reikvam H, Brenner AK, Hagen KM, et al. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15:530–541. doi:10.1016/j.scr.2015.09.008
   PubMed Web of Science ®Google Scholar
• Oliveira Miranda D, Soares de Lima TA, Ribeiro Azevedo L, Feres O, Ribeiro da Rocha JJ, Pereira-da-Silva G. Proinflammatory cytokines correlate with depression and anxiety in colorectal cancer patients. Biomed Res Int. 2014;2014:739650. doi:10.1155/2014/739650
   PubMed Web of Science ®Google Scholar